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A Ab bs st tr ra ac ct t
Epidemiologic research conducted over the last two decades has led us to believe that inherited factors play
an important role in the aetiology of prostate cancer, but the genes which underlie the inherited susceptibility
are elusive. The most compelling associations to date are with genes involved in DNA damage repair, including
BRCA2. In Poland we have initiated a programme to identify DNA variants which confer an increased risk of
prostate cancer and other cancers. Here we review our recent results. We found that germline mutations in
BRCA1, CHEK2 and NBS1 confer an increased prostate cancer risk in Polish men. We provide evidence that
CHEK2 is a multi-organ cancer susceptibility gene. We show that inherited variation in RNASEL and MSR1 genes
do not contribute to prostate cancer development in Poland.
I In nt tr ro od du uc ct ti io on n
Research conducted over the last two decades has led
us to believe that inherited factors play an important role
in the aetiology of cancer [1-8]. Prostate cancer is among
the leading causes of morbidity and mortality in men.
Relatively little is known about the genetic determinants of
this disease, but epidemiologic data suggest that dominant
susceptibility genes may be responsible for up to 5% of
all of cases [9-10]. Through linkage analysis, numerous
chromosomal loci have been identified, but no clear
prostate susceptibility gene has emerged. Three candidate
susceptibility genes have been positionally cloned – HPC1,
HPC2/ELAC2 and MSR1 – but a clear role for any of these
genes in hereditary prostate cancer has not been
established [11, 12]. There is evidence that rare mutations
of genes in the DNA damage signalling pathway and cell
cycle control pathway (BRCA2,  CHEK2 and  NBS1)
predispose to prostate cancer, but the contribution of these
two genes to prostate cancer aetiology is relatively small
[13]. Common variants in the genes in these pathways
(CDKN1B, CDKN1A, ATMATM, XRCC1, ERCC2) also
have been associated with an increased risk of prostate
cancer [14-16]. The DNA damage signalling and cell
cycle control pathways play a crucial role in the
maintenance of the integrity of the genome in response
to DNA damage and has been implicated in the
pathogenesis of prostate cancer and of cancers at other
sites. This paper reviews a range of studies which have
been performed in Polish population with the following
objectives:
1) to investigate the association between inherited
variation in RNASEL, MSR1, NBS1 and BRCA1 genes
and prostate cancer risk in the Polish population;
2)  to investigate the role of CHEK2 mutations in
inherited susceptibility to prostate cancer and
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T Ta ab bl le e   1 1. .   Comparison of the frequency of variants in RNASEL and MSR1 genes in 737 patients with prostate cancer and 511 individuals
from control group
G Ge en ne e V Va ar ri ia an nt t G Ge en no ot ty yp pe e N Nu um mb be er r   o of f   c ca ar rr ri ie er rs s   ( (f fr re eq qu ue en nc cy y) ) O OR R 9 95 5% %   C CI I p p
c ca as se es s c co on nt tr ro ol ls s
( (n n= =7 73 37 7) ) ( (n n= =5 51 11 1) )
N No o. .   ( (% %) ) N No o. .   ( (% %) )
1385G>A
GG 245 (33.3) 177 (34.6) 0.9 0.7-1.2 0.6
(R462Q)
GA 376 (51.0) 252 (49.3) 1.1 0.9-1.3 0.6
RNASEL
AA 116 (15.7) 82 (16.1) 1.0 0.7-1.3 0.9
1623T>G
TT 111 (15.1) 84 (16.4) 0.9 0.7-1.2 0.5
(D541E)
TG 372 (50.5) 259 (50.7) 1.0 0.8-1.2 1.0
GG 254 (34.4) 168 (32.9) 1.1 0.8-1.4 0.6
MSR1 945C>G CC 663 (90.0) 474 (92.8) 0.7 0.5-1.1 0.1
(P275A) CG 74 (10.0) 37 (7.2) 1.4 0.9-2.2 0.1
999C>T CC 725 (98.4) 503 (98.4) 1.0 0.4-2.4 1.0
(R293X)
CT 12 (1.6) 8 (1.6) 1.0 0.4-2.6 1.0
CI – confidence interval; OR – odds ratio; p – p-value
1 1. .   I In nh he er ri it te ed d   v va ar ri ia at ti io on n   i in n   R RN NA AS SE EL L, ,   M MS SR R1 1, ,
N NB BS S1 1 a an nd d   B BR RC CA A1 1 g ge en ne es s   a an nd d   p pr ro os st ta at te e   
c ca an nc ce er r   r ri is sk k   i in n   t th he e   P Po ol li is sh h   p po op pu ul la at ti io on n
1 1..1 1..  D DN NA A  v va ar ri ia an nt ts s  i in n  R RN NA AS SE EL L a an nd d  M MS SR R1 1 g ge en ne es s  
a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  p pr ro os st ta at te e  c ca an nc ce er r
(based on: Cybulski C, Woko³orczyk D, Jakubowska A, Gliniewicz
B, Sikorski A, Huzarski T, Debniak T, Narod SA, Lubiñski J. DNA
variation in MSR1, RNASEL and E-cadherin genes and prostate
cancer in Poland. Urol Int 2007; 79: 44-49)
RNASEL and MSR1 were identified through linkage
studies of prostate cancer families. Two mutations in
RNASEL (Met1Ile and Glu265X) were originally
described in familial prostate cancer cases from the
USA [17]. Other more common variants in RNASEL
(R462Q and D541E) were found to influence the risk
of prostate cancer in men [18]. Germline mutations in
the MSR1 gene (six rare missense variants and R293X
truncating mutation) were first shown to segregate with
hereditary prostate cancer in the USA. Common
polymorphisms in MSR1 have been associated with
increased prostate cancer risk [19]. To date, the roles
of RNASEL or MSR1 genes in prostate cancer aetiology
have not been investigated in Slavic populations. We
investigated if inherited variation in these genes
influences prostate cancer risk in Poland.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
The case group consisted of 737 prostate cancer
cases. Of the 737 cases, 506 were from Szczecin and
231 were from other countries (Opole, Bialystok,
Olsztyn). Study subjects were unselected for age or
family history. Family histories were obtained from each
subject. 110 patients had one or more first- or second-
degree relatives with prostate cancer (familial cases).
The control group consisted of 511 unselected healthy
elderly men aged 50 and above, taken from three
family doctors practicing in Szczecin. None of the
controls had cancer.
The polymorphisms in MSR1 and RNASEL were
selected after sequencing of the entire coding region of
these genes in 52 and 94 Polish men with familial
prostate cancer, respectively. Sequencing revealed only
two variants in the RNASEL gene (R462Q and D541E)
and two variants in the coding sequence of the MSR1
gene (P275A and R293X). These DNA variants were then
genotyped by restriction fragment length polymorphism
polymerase chain reaction (RFLP-PCR) using the restriction
enzymes AvaI (R462Q variant), MboI (D541E variant),
Hpy8I (P275A variant) and MvaI (R293X variant).
R Re es su ul lt ts s
The prevalence of the sequence variants in cases and
controls is shown is Table 1. The R462Q and D541E
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variants of RNASEL were seen in similar frequency in
cases and controls. We saw a trend towards a higher
frequency of the P275A variant in unselected cases than
in controls (10 vs. 7.2%; OR=1.4, p=0.1). A truncating
MSR1 R293X mutation was present in 1.6% of controls,
and 1.6% of unselected cases.
1 1..2 2..  G Ge er rm ml li in ne e  6 65 57 7d de el l5 5  m mu ut ta at ti io on n  i in n  t th he e  N NB BS S1 1 g ge en ne e  
a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  p pr ro os st ta at te e  c ca an nc ce er r
(based on: Cybulski C, Górski B, Debniak T, Gliniewicz B,
Mierzejewski M, Masojæ B, Jakubowska A, Matyjasik J, Z³owocka E,
Sikorski A, Narod SA, Lubiñski J. NBS1 is a prostate cancer
susceptibility gene. Cancer Res 2004; 64: 1215-1219)
Individuals with inherited recessive clinical
syndromes, such as Nijmegen breakage syndrome
(NBS), which is characterized by spontaneous
chromosomal instability, immunodeficiency and 
a predisposition to cancer, carry a mutation in one of
the genes in the DNA damage signalling pathway [20].
The product of the NBS1 gene is responsible for DNA
damage repair [21].
A 5-bp deletion in exon 6 of NBS1 (657del5) is
present in the majority of NBS patients from Eastern
Europe [22]. This variant is present in approximately
0.6% of individuals (heterozygous carriers) from the
general population in Poland [23, 24]. It has been
suggested that heterozygous carriers of the founder
mutation of NBS (657del5 allele) might be at increased
risk of cancer [25, 26], but prostate cancer specifically
has not been studied to date.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
The case group consisted of 340 men diagnosed
with prostate cancer at the University Hospital in
Szczecin. Family histories of cancer were obtained from
each subject. Thirty-five patients had one or more first-
or second-degree relatives with prostate cancer (familial
cases). We also included a second set of 21 familial
cases of prostate cancer from men who were referred
for evaluation at the Hereditary Cancer Centre by
family doctors or urologists because of familial
aggregation of prostate cancers. There were 1500
unaffected control subjects. One thousand control
subjects were selected at random from the
computerized patient lists of three family practices in
Szczecin. A second control group comprised 500
newborns from Szczecin for whom a sample of
umbilical cord blood was obtained.
Allele-specific PCR was used to detect the NBS1
founder mutation in DNA isolated from peripheral
blood leukocytes of cases and controls. A separate
DNA sample was sequenced to confirm the presence
of the NBS1 mutation.
For the loss of heterozygosity (LOH) studies, for each
of the nine prostate cancers in men with an NBS1
mutation, a single non-carrier control tumour was
selected. The control subject was born within 2 years of
the patient and had a tumour of the same Gleason score
as the matched patient. DNA was obtained from eight
of the nine paraffin-embedded, microdissected tumours
from NBS1 mutation carriers and from all of the nine
non-carrier control subjects. For the LOH analyses, two
primer pairs were used, corresponding to the
polymorphic microsatellite markers D8S88 and
D8S1811. PCR was performed using fluorescent primers.
PCR products were separated in an ABI PRISM 377 DNA
Sequencer (Applied Biosystems). Data collection and
analysis were performed using ABI PRISM 377 Collection
Software and GenScan Analysis Software Version 3.0
(Applied Biosystems). A signal reduction in one allele of
at least 70% was taken as the threshold of recognition
for LOH. The NBS1 mutant allele is five nucleotides
shorter than the wild-type NBS1 allele. For the LOH
analysis of mutation-positive cases, additional primers
were designed specifically to amplify exon 6 of NBS1,
which contains the deleted sequence. PCR conditions
using this primer set were as for allele-specific PCR. This
primer set generates two distinct fragments from
constitutional DNA from men with an NBS1 deletion.
R Re es su ul lt ts s
The NBS1 mutation was present in 9 of 340
unselected patients with prostate cancer (2.6%)
compared with only 9 of 1500 (0.6%) control subjects
from the general population (OR=4.5; p=0.002). The
657del5 germline mutation was present in 5 of the 56
(9%) familial cases (OR=16; p<0.0001). We
investigated the segregation of the NBS1 mutant allele
with prostate cancer in four families. We were able to
establish the mutation status in two affected males from
each family; in each family, the NBS1 mutation was
present in both affected members (Figure 1).
To analyze whether the wild-type allele of NBS1 is
lost in prostate cancer, we performed LOH analysis of
microdissected prostate tumours from eight patients
who carried the NBS1 mutation and from nine patients
who were found not to carry the NBS1 mutation. The
wild-type NBS1 allele was lost in seven of eight prostate
tumours from carriers of the 657del5 allele, but loss
of heterozygosity was seen in only one of nine tumours
from noncarriers (p=0.003).
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F Fi ig g. .   1 1. .   Pedigrees of NBS1 mutation positive cases with familial prostate cancer
1 1..3 3..  G Ge er rm ml li in ne e  m mu ut ta at ti io on ns s  i in n  t th he e  B BR RC CA A1 1g ge en ne e  a an nd d  s su us sc ce ep pt ti ib bi il li it ty y
t to o  p pr ro os st ta at te e  c ca an nc ce er r
(on based: Cybulski C, et al. BRCA1 mutations and prostate cancer
in Poland. Eur J Cancer Prev 2007 – in press)
BRCA1 mutations confer high risk of breast and
ovarian cancer [27]. Several studies suggested an
increased risk of prostate cancer in Ashkenazi Jewish
men with a BRCA1 mutation (185delAG or 5382insC)
[28-30]. Other studies, in non-Jewish populations,
have found little or no evidence of an increased risk
for prostate cancer in BRCA1 carriers [31-34]. In
Poland, there are three common founder alleles in
BRCA1 (C61G, 4153delA and 5382insC), which, in
total, account for 90% of all BRCA1 mutations [27].
Here we investigated if Polish men who carry one of
these three alleles in BRCA1 are at an increased risk
of prostate cancer.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
P Pa at ti ie en nt ts s
The case group consisted of 1793 unselected
prostate cancer cases, collected in 13 centres situated
throughout Poland (Szczecin, Bialystok, Olsztyn, Opole,
Koszalin, Gdansk, Lublin, Lodz, Warszawa, Wroclaw,
Blackened symbols – individuals with cancer; the type of
cancer and age of diagnosis are indicated next to the symbol:
CSU – primary cancer site unknown
+ NBS1 mutation carriers
• deceased men with prostate cancer who were likely to be
NBS1 mutation carriers
– absence of the mutation
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T Ta ab bl le e   2 2. .   Comparison of the frequency of BRCA1 mutations in 1793 patients with prostate cancer and 4570 controls
M Mu ut ta at ti io on n N Nu um mb be er r   o of f   c ca ar rr ri ie er rs s   ( (f fr re eq qu ue en nc cy y) ) O OR R 9 95 5% %   C CI I p p
c ca as se es s   ( (n n= =1 17 79 93 3) ) c co on nt tr ro ol ls s   ( (n n= =4 45 57 70 0) )
N No o. .   ( (% %) ) N No o. .   ( (% %) )
BRCA1 8 (0.45) 22 (0.48) 0.9 0.4-2.1 1.0
C61G 3 (0.17)  3 (0.07) 2.6 0.5-12.7 0.5
4153delA 4 (0.22) 2 (0.04) 5.1 0.9-27.9 0.1
5382insC 1 (0.06) 17 (0.37) 0.15 0.02-1.1 0.06
C61G or 7 (0.39) 5 (0.11) 3.6 1.1-11.3 0.045
4153delA*
CI – confidence interval; OR – odds ratio; p – p-value
*when 5382insC is excluded, as unlikely pathogenic for prostate cancer in the Polish population
Poznan, Rzeszow, Sucha Beskidzka). Study subjects were
unselected for age or family history. Family histories
were obtained from each participant. Two hundred and
twenty-nine patients had one or more first- or second-
degree relative with prostate cancer (familial cases).
The control group consisted of a mix of 2000
newborn children from 10 hospitals throughout Poland
(Szczecin, Bialystok, Gorzow, Katowice, Wroclaw, Poznan,
Opole, Lodz and Rzeszow), 1570 adults selected at
random from the patient lists of three family doctors
practicing in the Szczecin region and 1000 individuals
from Szczecin who submitted blood for paternity testing.
In total there were 4570 population controls.
M Me et th ho od ds s
The 4153delA and 5382insC mutations were
detected using a multiplex-specific polymerase chain
reaction (PCR) assay. The third mutation (C61G)
generates a novel restriction enzyme site in exon 5.
This mutation is detected after digesting amplified DNA
with AvaII. All mutations were confirmed by sequencing.
R Re es su ul lt ts s
A BRCA1 mutation was seen in eight of 1793
(0.45%) cases and in 22 of 4570 (0.48%) controls
(OR=0.9; p=1.0) – Table 2. 5382insC is the most
frequent mutation of the three Polish founder mutations.
The 5382insC mutation was detected only in 0.06%
of cases, compared with 0.37% of controls (OR=0.15;
p=0.06). In contrast, 4153delA was more common
in cases than in controls (0.22 vs. 0.04%; OR=5.1;
p=0.1). The C61G mutation was also more frequent
in cases than in controls (0.17 vs. 0.07%; OR=2.6;
p=0.5). A statistical test of homogeneity of the OR
rejected the null hypothesis that the ORs associated
with the three mutations were similar (p=0.008).
A BRCA1 mutation was found in three of 229 (1.3%)
familial prostate cancer cases, compared with five of 4570
controls (OR=12; 95% confidence interval (CI) 2.9–51;
p=0.0004). The 4153delA mutation was present in one
familial case (OR=10.0; p=0.3) and C61G was
responsible for two other prostate cancer families
(OR=13.4; p=0.008). The family with the 4153delA
mutation contained two men with prostate cancer and the
families with the C61G mutation contained four and five
men with prostate cancer. The C61G segregated with
prostate cancer in the two families (Figure 2).
2 2. .   G Ge er rm ml li in ne e   m mu ut ta at ti io on ns s   i in n   t th he e   C CH HE EK K2 2 g ge en ne e
a an nd d   t th he ei ir r   a as ss so oc ci ia at ti io on n   
w wi it th h   p pr re ed di is sp po os si it ti io on n   t to o   p pr ro os st ta at te e   c ca an nc ce er r
a an nd d   t tu um mo ou ur rs s   o of f   o ot th he er r   s si it te es s   o of f   o or ri ig gi in n
2 2..1 1..  I Id de en nt ti if fi ic ca at ti io on n  o of f  p po oi in nt t  m mu ut ta at ti io on ns s  i in n  t th he e  C CH HE EK K2 2 g ge en ne e  
i in n  t th he e  P Po ol li is sh h  p po op pu ul la at ti io on n
(based on: Cybulski C, Huzarski T, Górski B, Masojæ B, Mierzejewski M,
Debniak T, Gliniewicz B, Matyjasik J, Z³owocka E, Kurzawski G, 
Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubiñski J. 
A novel founder CHEK2 mutation is associated with increased prostate
cancer risk. Cancer Res 2004; 64: 2677-2679)
Germline mutations in the CHEK2 gene have been
described in several populations. For example, in the
United States, 18 different CHEK2 mutations were found
[35]. Two founder variants in the CHEK2 gene (1100delC
and I157T) are present in Finland [36]. In the Ashkenazi
Jewish population, a single S428F mutation was detected
[37]. In order to identify CHEK2 variants present in the
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Polish population, we screened the entire coding CHEK2
sequence in 140 men with prostate cancer.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s  
The case group consisted of 140 prostate cancer
patients (including 44 familial cases). The entire
coding region of the CHEK2 gene was sequenced
using primers and conditions described previously
[35].
R Re es su ul lt ts s
Three mutations were detected, the I157T missense
variant and two truncating mutations IVS2+1G>A and
1100delC.
F Fi ig g. .   2 2. .   Pedigrees of BRCA1 mutation positive cases with familial prostate cancer
Blackened symbols – individuals with cancer; the
type of cancer and age of diagnosis are indicated
next to the symbol:
CSU – primary cancer site unknown
+ BRCA1 mutation carriers
• deceased men with prostate cancer who were
likely to be BRCA1 mutation carriers
– absence of the mutation
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2 2..2 2..  I Id de en nt ti if fi ic ca at ti io on n  o of f  l la ar rg ge e  d de el le et ti io on n  o of f  e ex xo on ns s  9 9  a an nd d  1 10 0  
o of f  t th he e  C CH HE EK K2 2 g ge en ne e  i in n  t th he e  P Po ol li is sh h  p po op pu ul la at ti io on n
(based on: Cybulski C, Woko³orczyk D, Huzarski T, Byrski T, 
Gronwald J, Górski B, Debniak T, Masojæ B, Jakubowska A, 
Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, 
Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P , Bar K,
Klijer R, Zdrojowy R, Ma³kiewicz B, Borkowski A, Borkowski T, Szwiec
M, Narod SA, Lubiñski J. A large germline deletion in the CHEK2 kinase
gene is associated with an increased risk of prostate cancer. J Med
Genet 2006; 43: 863-866)
Recently, a large deletion in CHEK2 was identified
in several unrelated patients with breast cancer of Czech
or Slovak origin. Haplotype analysis confirmed that the
mutation had a single source. The geographical and
ethnic extent of this founder allele has not yet been
determined [38]. We sought to establish if this deletion
is present in the Polish population.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
Three samples of pooled DNA, each including
pooled DNA from about 500 people from Poland,
were amplified with primers described previously for
the detection of the deletion of exons 9 and 10 [38].
Ninety unpooled DNA samples representing individual
controls were also included.
Short extension times (2 min) were applied during
polymerase chain reaction (PCR) to amplify only a short
allele containing the large deletion. A single PCR
product of about 1.3 kb was amplified from all samples
with the pooled DNA. The short product was seen in
1 of 90 DNA samples from single patients. The PCR
products from all positive cases were sequenced.
R Re es su ul lt ts s
A large deletion of exons 9 and 10 of the CHEK2
gene (del5395) is also a founder mutation in Poland. 
A single PCR product of about 1.3 kb was amplified from
all samples with the pooled DNA. The short product was
seen in 1 of 90 DNA samples from single patients. The
PCR products from all positive cases were sequenced.
The deletion breakpoints were characterized at 
a nucleotide level (Figure 3). By our estimate, the length
of this deletion is 5395 bp, and not 5567 bp as
described in the original report [38].
2 2..3 3..  C CH HE EK K2 2 m mu ut ta at ti io on ns s  a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  p pr ro os st ta at te e  c ca an nc ce er r
(based on: Cybulski C, Woko³orczyk D, Huzarski T, Byrski T, 
Gronwald J, Górski B, Debniak T, Masojæ B, Jakubowska A,
Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, 
Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P , 
Bar K, Klijer R, Zdrojowy R, Ma³kiewicz B, Borkowski A, Borkowski T,
Szwiec M, Narod SA, Lubiñski J. A large germline deletion in the
CHEK2 kinase gene is associated with an increased risk of prostate
cancer. J Med Genet 2006; 43: 863-866)
CHEK2 gene mutations have been associated with
an increased prostate cancer risk in men from the
United States [35] and Finland [39], but the Polish
population has not been studied. In this study, we
investigated whether CHEK2 plays an important role
in the development of prostate cancer in Poland.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
We studied 1864 prostate cancer cases diagnosed
between 1999 and 2005 in 13 centres situated
throughout Poland. All the cases were unselected by
age and family history. To estimate the frequency of the
Polish founder mutations in the general population,
three control groups were combined. The first group
consisted of 2183 newborn children from 10 cities in
Poland (Szczecin, Bialystok, Gorzow, Katowice,
Wroclaw, Poznan, Opole, Lodz and Rzeszow) between
2003 and 2006. Samples of cord blood from
unselected infants were forwarded to the study centre
in Szczecin. The second control group included healthy
adult patients (1079 women and 817 men) of three
family doctors practicing in the Szczecin region. The
third control group consisted of 1417 young adults
(705 women and 712 men) from Szczecin who
submitted blood for paternity testing.
Large deletion of exons 9 and 10 was genotyped
in multiplex PCR reaction. The I157T and IVS2+1G>A
B B. .
Telomeric breakpoint TGA GAC TCT GCC TCA A AA A AAA AAA AAA AAT A
Deletion sequence TGA GAC TCT GCC TCA A AA A CCT GGC CAA CAT G
Centromeric breakpoint CAG GAG TTT GAG ACC A AA A CCT GGC CAA CAT G
F Fi ig g. .   3 3. .   A 5395 bp deletion of exons 9 and 10 of CHEK2 detected
in the Polish population: A A – sequencing chromatogram of PCR
product containing the deletion; B B – location of deletion breakpoints
on chromosome 22 in Alu-repeats (shown in bold)
A A. .
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variants were analyzed by restriction fragment length
polymorphism PCR. 1100delC was analyzed using an
allele-specific PCR assay. Positive results were
confirmed by sequencing.
R Re es su ul lt ts s
Protein truncating mutations in the CHEK2 gene
(del5395, 1100delC, IVS2+1G>A) were more
frequent in 1864 men with prostate cancer than in
5496 control individuals (2.4 vs. 1.1%; OR=2.3;
p<0.0001). The I157T missense mutation was also
more common in unselected cases than in controls
(7.6 vs. 4.8%; OR=1.6; p<0.0001). The frequency
of CHEK2 mutations was also found to be higher in 
a series of 249 familial prostate cancer cases than in
controls, both for truncating variants (4.8 vs. 1.1%;
OR=4,7; p<0.0001) and the I157T missense variant
(12.0 vs. 4.8%; OR=2.7; p<0.0001) (Table 3).
2 2..4 4..  C CH HE EK K2 2 m mu ut ta at ti io on ns s  a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  b br re ea as st t  c ca an nc ce er r
(based on: Cybulski C, Woko³orczyk D, Huzarski T, Byrski T,
Gronwald J, Górski B, Debniak T, Masojæ B, Jakubowska A, van de
Wetering T, Narod SA, Lubiñski J. A deletion in CHEK2 of 5,395 bp
predisposes to breast cancer in Poland. Breast Cancer Res Treat
2007; 102:119-122)
A founder allele in CHEK2, 1100delC, has been
reported to be a low-penetrance breast cancer
susceptibility allele in several studies, and in many
ethnic groups [37, 40-45]. Other CHEK2 variants
(IVS2+1G>A, I157T, and S428F) have also been
suggested to confer increased breast cancer risks [44,
45]. Recently, a large deletion of exons 9 and 10 of
T Ta ab bl le e   3 3. .   Comparison of the frequency of CHEK2 mutations in prostate cancer patients and in the control group
M Mu ut ta at ti io on n G Gr ro ou up p N Nu um mb be er r   o of f   c ca ar rr ri ie er rs s/ /n nu um mb be er r   o of f   t te es st te ed d    O OR R 9 95 5% %   C CI I p p
( (f fr re eq qu ue en nc cy y, ,   % %) )
controls 24/5496 (0.4) 1.0
del5395 unselected cases 15/1864 (0.8) 1.9 0.97-3.5 0.009
familial cases 4/249 (1.6) 3.7 1.3-10.8 0.03
controls 12/5496 (0.2) 1.0
1100delC unselected cases 14/1864 (0.8) 3.5 1.6-7.5 0.002
familial cases 3/249 (1.2) 5.6 1.6-19.9 0.02
controls 22/5496 (0.4) 1.0
IVS2+1G>A unselected cases 15/1864 (0.8) 2.0 1.05-3.9 0.052
familial cases 5/249 (2.0) 5.1 1.9-13.6 0.002
Protein
controls 58/5496 (1.1) 1.0
truncating unselected cases 44/1864 (2.4) 2.3 1.5-3.4 <0.0001
mutation*
familial cases 12/249 (4.8) 4.7 2.5-9.0 <0.0001
controls 264/5496 (4.8) 1.0
I157T unselected cases 142/1864 (7.6) 1.6 1.3-2.0 <0.0001
familial cases 30/249 (12.0) 2.7 1.8-4.1 <0.0001
controls 321/5496 (5.8) 1.0
CHEK2** unselected cases 184/1864 (9.9) 1.8 1.5-2.1 <0.0001
familial cases 42/249 (16.9) 3.3 2.3-4.6 <0.0001
CI – confidence interval; OR – odds ratio; p – p-value
*one of the three truncating mutations (del5395, IVS2+1G>A, 1100delC)
**any CHEK2 mutation (del5395, IVS2+1G>A, 1100delC, I157T)
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T Ta ab bl le e   4 4. .   Comparison of CHEK2 mutation frequency in women with breast cancer and in controls
M Mu ut ta at ti io on n G Gr ro ou up p N Nu um mb be er r   o of f   c ca ar rr ri ie er rs s/ /n nu um mb be er r   o of f   t te es st te ed d O OR R 9 95 5% %   C CI I p p
( (f fr re eq qu ue en nc cy y, ,   % %) )
controls 24/5496 (0.4) 1.0
del5395 unselected cases 19/1978 (1.8) 2.2 1.2-4.0 0.01
early onset cases 28/3229 (0.9) 2.0 1.2-3.4 0.02
controls 12/5496 (0.2) 1.0
1100delC unselected cases 10/1978 (0.6) 2.3 1.0-5.4 0.08
early onset cases 16/3228 (0.5) 2.3 1.1-4.8 0.04
controls 22/5496 (0.4) 1.0
IVS2+1G>A unselected cases 21/1978 (1.1) 2.7 1.5-4.9 0.002
early onset cases 31/3228 (1.0) 2.4 1.4-4.2 0.002
Protein
controls 58/5496 (1.1) 1.0
truncating unselected cases 49/1978 (2.5) 2.4 1.6-3.5 <0.0001
mutation*
early onset cases 74/3228 (2.3) 2.2 1.6-3.1 <0.0001
controls 264/5496 (4.8) 1.0
I157T unselected cases 134/1978 (6.8) 1.4 1.2-1.8 0.001
early onset cases 207/3228 (6.4) 1.4 1.1-1.6 0.002
controls 321/5496 (5.8) 1.0
CHEK2** unselected cases 180/1978 (9.1) 1.6 1.3-2.0 <0.0001
early onset cases 279/3228 (8.6) 1.5 1.3-1.8 <0.0001
CI – confidence interval; OR – odds ratio; p – p-value
*one of the three truncating mutations (del5395, 1100delC, IVS2+1G>A)
**any CHEK2 mutation (del5395, 1100delC, IVS2+1G>A, I157T)
CHEK2 was identified in two USA families at high risk
of breast cancer [38]. The aim of the study was to
establish the relationship between CHEK2 mutations
and the risk of breast cancer Poland.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
This study included prospectively ascertained cases
of invasive breast cancer diagnosed throughout Poland
from 1996 to 2003. The case group consisted of two
groups of women with breast cancer. The first group
had 3228 cases diagnosed at age 50 or below. The
second group included a sample of 1978 patients,
unselected for age. Of these, 752 were under the age
of 51 and were also enrolled in the early-onset study
described above. All cases were unselected for family
history. The control group consisted of 5496 patients.
The controls are described in detail in section 2.3.
Genotyping methods are described in detail in
section 2.3.
R Re es su ul lt ts s
Protein truncating mutations (del5395, 1100delC,
IVS2+1G>A) were observed more frequently in 1978
unselected breast cancer cases compared to controls
(2.3 vs. 1.1%; p<0.0001). The frequency of missense
variant I157T (p=0.0001) was also greater among
unselected breast cancer cases than in the control
group (6.8 vs. 4.8%; p=0.001). The odds ratio for
breast cancer associated with truncating mutations
(OR=2.4) was greater than that associated with the
missense variant I157T (OR=1.4) – Table 4.
Protein-truncating mutations (del5395, 1100delC,
IVS2+1G>A) were detected in 2.2% of 3228 patients
with breast cancer diagnosed before the age of 51.
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T Ta ab bl le e   5 5. .   Comparison of CHEK2 mutation frequency in patients with colorectal cancer and controls
M Mu ut ta at ti io on n G Gr ro ou up p N Nu um mb be er r   o of f   c ca ar rr ri ie er rs s/ /n nu um mb be er r   o of f   t te es st te ed d O OR R 9 95 5% %   C CI I p p
( (f fr re eq qu ue en nc cy y, ,   % %) )
Protein
controls 58/5496 (1.1) 1.0
truncating unselected cases 11/1058 (1.0) 1.0 0.5-1.8 0.9
mutation*
familial cases 2/110 (1.8) 1.7 0.4-7.2 0.44
controls 264/5496 (4.8) 1.0
I157T unselected cases 77/1085 (6.6) 1.5 1.2-2.0 0.002
familial cases 11/110 (10) 2.2 1.2-4.1 0.01
CI – confidence interval; OR – odds ratio; p – p-value
*one of the three truncating mutations (del5395, 1100delC, IVS2+1G>A)
This frequency was significantly higher (p<0.0001)
than in the control group (1.1%). The missense variant
I157T was also significantly more common (p=0.002)
among patients with early onset breast cancer (6.4%)
than in controls (4.8%). The odds ratio for early onset
breast cancer associated with a truncating CHEK2
mutation (OR=2.2) was greater than that associated
with the I157T mutation (OR=1.4) – Table 4.
2 2..5 5..  C CH HE EK K2 2 m mu ut ta at ti io on ns s  a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  c co ol lo or re ec ct ta al l  c ca an nc ce er r
(based on: Cybulski C, Woko³orczyk D, K³adny J, Kurzawski G, 
Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Górski B,
D Ecedil Bniak T, Narod SA, Lubiñski J. Germline CHEK2 mutations
and colorectal cancer risk: different effects of a missense and
truncating mutations? Eur J Hum Genet 2007; 15: 237-241)
Germline mutations in CHEK2 have been associated
with a range of cancer types, in particular of the breast
and the prostate [35-47]. Protein-truncating mutations
in CHEK2 have been reported to confer higher risk of
cancer of the breast and the prostate than the missense
I157T variant. Recent studies from Finland suggest an
increased risk of colon cancer among carriers of
missense variant I157T, but not in carriers of CHEK2
protein truncating mutations [36].
The aim of the study was to evaluate the association
between specific CHEK2 alleles and colon cancer.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
We studied 1085 colorectal cancer cases
diagnosed between 1998 and 2005 in three centres
in North-Western Poland. Patients were unselected for
age and family history. 964 colon cancer cases were
diagnosed in Szczecin and 121 cases were diagnosed
in Koszalin and Kolobrzeg. One hundred and ten cases
had first-degree relatives diagnosed with colon cancer
(familial cases). The control group consisted of 5496
patients. The controls are described in detail in section
2.3. Genotyping methods are described in detail in
section 2.3.
R Re es su ul lt ts s
The missense mutation I157T was overrepresented
both in unselected cases (6.6%) and familial cases (10%)
with colorectal cancer compared to controls (4.8%). The
OR for unselected colorectal cancer cases with the
missense mutation I157T was 1.5 (p=0.002) – Table 5.
The OR for familial cases with the I157T variant was 2.2
(p=0.01). We saw no association between colorectal
cancer risk and CHEK2 truncating alleles.
2 2..6 6..  C CH HE EK K2 2 m mu ut ta at ti io on ns s  a an nd d  s su us sc ce ep pt ti ib bi il li it ty y  t to o  t tu um mo ou ur rs s  
o of f  o ot th he er r  s si it te es s  o of f  o or ri ig gi in n
(based on: Cybulski C, Górski B, Huzarski T, Masojæ B, Mierzejewski
M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J,
Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek
K, Szymañska A, Szymañska J, Kurzawski G, Suchy J, Oszurek O,
Witek A, Narod SA, Lubiñski J. CHEK2 is a multiorgan cancer
susceptibility gene. Am J Hum Genet 2004; 75: 1131-1135)
CHEK2 mutations originally were found in families
with Li-Fraumeni syndrome [46, 47]. The CHEK2
protein is expressed in a wide range of tissues and
participates in the DNA damage response in many cell
types; therefore CHEK2 is a good candidate for 
a multi-site cancer susceptibility gene.
The aim of the study was to assess the range of
cancers associated with inactivating mutations in the
CHEK2 gene.
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of originH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(3) 174
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
To establish the range of cancer types associated
with CHEK2 mutations, we genotyped unselected cases
of cancer with the most common types of cancer in
Poland. In this part the results of 2001 cancer patients
are described (excluding cases of the prostate, breast
and colon cancers, which are described in detail in
previous sections).
The control group consisted of: 2 000 newborn
children from 10 hospitals throughout Poland (Szczecin,
Bialystok, Gorzow, Katowice, Wroclaw, Poznan, Opole,
Lodz and Rzeszow); 1000 adult patient lists of three
family doctors practicing in the Szczecin region; 1000
adults unselected from family history from Szczecin who
submitted blood for paternity testing.
Genotyping methods are described in detail in section
2.3. To confirm the chromosomal location of the
observed CHEK2 mutations, we analyzed the polymorphic
marker D22S275, which maps to intron 4 of CHEK2. We
genotyped: 36 patients with the I157T variant; 24 patients
with 1100delC; 52 patients with IVS2+1G>A and 50
individuals from the general population.
R Re es su ul lt ts s
The frequencies of the three CHEK2 variants in cases
and controls are presented in Table 6. Because of their
different effects on protein synthesis, the two truncating
mutations (IVS2+1G>A or 1100delC) were considered
separately from the missense mutation (I157T).
CHEK2 truncating alleles were associated with
increased risk of breast and prostate cancer (described
in the previous sections) and thyroid cancer (OR=4.9;
p=0.0006). The missense variant I157T was associated
with an increased risk of prostate, breast and colon
cancer (described in the previous sections) and in addition
with an increased risk of kidney cancer (OR=2.0;
p=0.0006) and thyroid cancer (OR=1.9; p=0.04).
Although any individual finding might be due to
chance, our study on the whole suggests that mutations
in CHEK2 increase the risk of cancer in many different
organs. A total of 52 comparisons were made. Of these,
13 were significant at the p=0.05 level (2.6 expected
by chance) and 5 were significant at the p=0.01 level
(0.5 expected). Furthermore, in all three sites for which
a significant association was seen with the truncating
mutation, a significant association was also seen with
the missense mutation. This would be unlikely to be the
case if the observations were due to chance.
To confirm the chromosomal location of the
observed  CHEK2 mutations we analyzed the
polymorphic marker D22S275, which maps to intron
4 of CHEK2. All individuals with the 1100delC variant
or with the I157T variant carried the 165 bp allele of
D22S275, which we estimate has a frequency of 15%
in the Polish population. All individuals with the
IVS2+1G>A mutation carried the 171bp allele of the
D22S275 marker, which we estimate has a frequency
of 8% in the general population. These observations
support the chromosome 22 assignment for the three
variant alleles.
2 2..7 7..  C Cl li in ni ic ca al l  c ch ha ar ra ac ct te er ri is st ti ic cs s  o of f  C CH HE EK K2 2- -p po os si it ti iv ve e  b br re ea as st t  c ca an nc ce er rs s
i in n  y yo ou un ng g  w wo om me en n  f fr ro om m  P Po ol la an nd d
(based on: Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J,
Debniak T, Wokolorczyk D, Jakubowska A, Kowalska E, Oszurek O,
Narod SA, Lubinski J. CHEK2-positive breast cancers in young Polish
women. Clin Cancer Res 2006; 12: 4832-4835)
A founder allele in CHEK2, 1100delC, has been
reported to be a low-penetrance breast cancer
susceptibility allele in several studies, and in many ethnic
groups. Recent studies reported that patients with the
CHEK2 1100delC variant had a 6-times higher risk of
contralateral breast cancer and 3-times higher risk of
distant metastasis [42, 48, 49] and more frequently
developed ER-positive tumours than non-carriers (91
vs. 69%; p=0.03) [48]. Although the relationship
between CHEK2 mutations and breast cancer is well
documented, little is known about clinical characteristic
of cancers in carriers of CHEK2 mutations.
To investigate the contribution of CHEK2 mutations
to early-onset breast cancer in Poland, and to establish
the characteristic features of these cancers, we compared
clinical and pathological features of CHEK2-positive and
CHEK2-negative breast cancers.
M Ma at te er ri ia al ls s  a an nd d  m me et th ho od ds s
The case group consisted of 3228 patients with
breast cancer diagnosed before age 50, unselected
from family history, who tested negative for BRCA1
mutation (4153delA, 5328insC, and C61G). The
medical and pathology reports of the cases were
reviewed locally by the physician associated with the
study and relevant information was forwarded to the
study centre in Szczecin. Information was recorded on
age at diagnosis, stage, grade and lymph node status,
oestrogen-receptor status, multicentricity and bilaterality.
The data were collected from at least 70% of patients.
Tumour blocks and/or paraffin-embedded slides were
requested from the corresponding pathology centres.
A central pathology review of was conducted in Szczecin
by two pathologists associated with the study.
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T Ta ab bl le e   6 6. .   Comparison of CHEK2 mutation frequency in patients with selected tumours and in the control group
L Lo oc ca at ti io on n   o or r   t ty yp pe e N Nu um mb be er r N Nu um mb be er r   o of f   m mu ut ta at ti io on n   c ca ar rr ri ie er rs s   ( (f fr re eq qu ue en nc cy y) ), ,
o of f   t tu um mo ou ur r o of f   t te es st te ed d r re es su ul lt ts s   o of f   s st ta at ti is st ti ic ca al l   a an na al ly ys si is s* *
I IV VS S2 2+ +1 1G G> >A A 1 11 10 00 0d de el lC C 1 11 10 00 0d de el lC C I I1 15 57 7T T
o or r   I IV VS S2 2+ +1 1G G> >A A
Bladder 172 1 (0.6%) 1 (0.6%) 12 (7.0%)
OR=1.2 0 OR=0.8 OR=1.5
p=0.7 p=0.8 p=0.3
Kidney 264 0 2 (0.8%) 2 (0.8%) 26 (9.8%)
OR=2.7 OR=1.0 OR=2.1
p=0.5 p=0.8 p=0.0006
Larynx 245 0 0 0 10 (4.1%)
OR=0.8
p=0.7
Lung 272 0 0 0 7 (2.6%)
OR=0.5
p=0.1
Melanoma 129 2 (1.5%) 1 (0.8%) 3 (2.3%) 6 (4.6%)
OR=3.3 OR=3.1 OR=3.2 OR=1.0
p=0.3 p=0.8 p=0.1 p=0.9
Ovary 292 0 0 0 14 (4.8%)
OR=1.0
p=0.9
Stomach 241 4 (1.7%) 0 4 (2.1%) 13 (5.4%)
OR=3.5 OR=2.3 OR=1.1
p=0.05 p=0.2 p=0.8
NHL 120 1 (0.8%) 0 1 (0.8%) 11 (9.2%)
OR=1.8 OR=1.1 OR=2.0
p=0.9 p=0.7 p=0.05
Pancreas 93 0 0 0 6 (6.4%)
OR=1.4
p=0.6
Thyroid 173 5 (2.9%) 1 (0.6%) 6 (3.5%) 15 (8.7%)
OR=6.2 OR=2.3 OR=4.9 OR=1.9
p=0.0003 p=0.9 p=0.0006 p=0.04
Controls 4000 19 (0.475%) 10 (0.25%) 29 (0.725%) 193 (4.825%)
*comparison of CHEK2 mutation frequency in patients with specific tumour type to that of control group
NHL – non-Hodgkin lymphoma; OR – odds ratio; p – p-value
R Re es su ul lt ts s
A CHEK2 mutation was identified in 252 of 3,228
women with breast cancer (7.8%), including I157T
(207 times), IVS2+1G>A (31 times), and 1100delC
(16 times). The mean age of diagnosis in women with
a CHEK2 mutation was similar to that of the non-
carrier cases. However, the mean age of diagnosis of
women with a truncating mutation was 1.8 years lower
than women without a CHEK2 mutation (42.5 vs. 44.3
years; p=0.01).
The characteristics of the breast cancer cases in the
252 women with a CHEK2 mutation are presented in
Table 7 and compared with non-carriers. Breast
cancers in women with a CHEK2 mutation were more
commonly of lobular histology (21.5 vs. 15.8%;
p=0.05), of size greater than 2 cm (54.8 vs. 43.5%;
p=0.01) or of multi-centric origin (28.7 vs. 19.5%;
p=0.01) than were cancers from women without 
a CHEK2 mutation. Intraductal cancers (DCIS) with
micro-invasion were also more common in women
with a CHEK2 mutation than in non-carriers (11.3 vs.
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T Ta ab bl le e   7 7. .   Comparison of breast cancers in patients with CHEK2 mutations to cancers in patients without CHEK2 mutations
F Fe ea at tu ur re e C CH HE EK K2 2- -p po os si it ti iv ve e   c ca as se es s C CH HE EK K2 2- -n ne eg ga at ti iv ve e   c ca as se es s p p
( (n n= =2 25 52 2) ) ( (n n= =2 29 97 76 6) )
Age in years (mean) 44.2 44.3 0.7
Age group 20-30 3.6% (9/252) 1.7% (52/2976) 0.07
31-40 15.9% (40/252) 17.2% (512/2976) 0.7
41-50 80.5% (203/252) 81% (2412/2976) 0.9
Histology ductal G1–2 grade 29.3% (54/186) 26.9% (622/2315) 0.6
ductal G3 grade 10.7% (20/186) 12.7% (294/2315) 0.5
medullary 2.1% (4/186) 4.9% (113/2315) 0.1
lobular 21.5% (40/186) 15.8% (366/2315) 0.05
tubulo-lobular 4.3% (8/186) 3.6% (83/2315) 0.8
DCIS 11.3% (21/186) 7.2% (168/2315) 0.06
other 4.8% (9/186) 5.1% (118/2315) 1.0
missing or unknown 16.7% (31/186) 23.8% (551/2315) 0.03
Pre-operative chemotherapy 27.7% (66/238) 24.5% (661/2693) 0.3
Oestrogen receptor positive 65.1% (97/149) 63.7% (1048/1646) 0.8
Tumour size (cm) <1 cm 5.9% (9/152) 11.2% (193/1728) 0.05
1-2 cm 40.1% (61/152) 45.3% (783/1728) 0.2
>2 cm 53.9% (82/152) 43.5% (752/1728) 0.01
Lymph nodes positive 45.0% (68/151) 40.1% (722/1777) 0.3
Multicentric 28.7% (41/143) 19.5% (316/1619) 0.01
Bilateral 2.3% (5/215) 3.3% (84/2531) 0.6
Family history positive* 13.8% (31/224) 8.9% (237/2652) 0.02
*family history refers to a first-degree relative of a proband affected with breast cancer
DCIS – intraductal cancer (ductal carcinoma in situ) with microinvasion; p – p-value
7.2%, p=0.06), but this difference was not significant.
Carriers and non-carriers were similar with respect to
oestrogen receptor status (65.1 vs. 63.7%; p=0.8) and
lymph node status (45 positive vs. 40.1%; p=0.3).
Bilateral tumours were equally common in both
subgroups (2.3 vs. 3.3%; p=0.6).
The great majority of women with a CHEK2
mutation did not have a strong family of cancer –
13.8% of the women with breast cancer and a CHEK2
mutation were from a family with two or more first-
degree relatives with breast cancer. However, this was
more frequent than reported by the non-carriers (8.9%)
and the difference was statistically significant (OR=1.6;
p=0.02).
3 3. .   S Su um mm ma ar ry y   o of f   t th he e   r re es su ul lt ts s
1. The entire coding region of the RNASEL gene was
sequenced in 94 men with familial prostate cancer
and the coding region of the MSR1 gene was
screened in 52 men with familial prostate cancer.
Four DNA variants were detected including R462Q
and D541E in the RNASEL gene, and P275A and
R293X in the MSR1 gene. These variants were
genotyped in a series of 737 unselected prostate
cancer cases and 511 controls, but no significant
differences in the allele frequencies were observed.
2. The NBS1 657del5 mutation was present in 2.6% of
340 unselected patients with prostate cancer
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compared with only 0.6% of 1500 control subjects
from the general population (OR=4.5; p=0.002).
The 657del5 germline mutation was present in 9%
of 56 men with familial prostate cancer (OR=16;
p<0.0001). The 657del5 mutation segregated with
disease in four families with familial prostate caner.
Loss of the wild type NBS1 allele was observed in
seven of eight tumours from men who carried 
a germline NBS1 deletion compared with only one
of nine NBS1 mutation-negative prostate tumours
(p=0.003).
3. The 5382insC mutation in the BRCA1 gene was
detected only in one of 1793 prostate cancer cases
(0.06%), whereas it was seen in 0.37% of 4570
controls (p=0.06). In contrast, the 4153delA and
C61G mutations were found in excess in cases
(0.39%) compared to controls (0.11%). The
presence of either of these alleles (C61G or
4153delA) was associated with an increased risk
for prostate cancer (OR=3.6; p=0.045), in
particular for familial prostate cancer (OR=12;
p=0.0004). Segregation analysis suggested that
the C61G mutation segregated with disease in two
families with familial prostate cancer. A statistical
test of homogeneity of the odds ratio revealed that
the risks associated with the three BRCA1 mutations
were different (p=0.008).
4.  Three point mutations in the CHEK2 gene
(1100delC, IVS2+1G>A, I157T) were detected by
sequencing of DNA isolated from peripheral blood
of 140 men with prostate cancer. Large germline
deletion of 5395 base pairs in length removing
exons 9 and 10 of the CHEK2 gene (del5395) was
detected by analysis of samples with pooled DNA,
each one including DNAs from approximately 500
individuals from Poland.
5. Protein truncating mutations in the CHEK2 gene
(del5395, 1100delC, IVS2+1G>A) were more
frequent in 1864 men with prostate cancer than in
5496 control individuals (2.4 vs. 1.1%; OR=2.3;
p<0.0001). The I157T missense mutation was also
more common in unselected cases than in controls
(7.6 vs. 4.8%; OR=1.6; p<0.0001). The frequency
of CHEK2 mutations was also found to be higher in
a series of 249 familial prostate cancer cases than in
controls, both for truncating variants (4.8 vs. 1.1%;
OR=4.7; p<0.0001) and the I157T missense variant
(12.0 vs. 4.8%; OR=2.7; p<0.0001).
6. Comparison of the frequency of CHEK2 variants in
7540 patients (4454 with breast cancer, 1085 with
colorectal cancer, 2001 with other tumours
excluding prostate cancer) to that in controls from
the general population revealed a positive
association of CHEK2 mutations with malignancies
of different site of origin. CHEK2 truncating alleles
were associated with an increased risk of cancer
development in the thyroid (OR=4.9; p=0.0006)
and the breast (OR=2.4; p=0.0001). The missense
variant I157T was associated with an increased risk
of breast cancer (OR=1.4; p=0.001), colon cancer
(OR=1.5; p=0.002), kidney cancer (OR=2.1;
p=0.0006) and thyroid cancer (OR=1.9; p=0.04).
The range of cancers associated with I157T
missense variant of the CHEK2 gene was greater
than that associated with CHEK2 truncating alleles.
7. Evaluation of 3228 unselected breast cancers
diagnosed under the age of 51 years revealed that
breast cancers in women with a CHEK2 mutation
were more commonly of lobular histology (21.5 vs.
15.8%; p=0.05), of size greater than 2 cm (54.8
vs. 43.5%; p=0.01) or of multi-centric origin (28.7
vs. 19.5%; p=0.01) than were cancers from women
without a CHEK2 mutation. In addition, mutation
carriers more frequently had a positive family history
of breast cancer than non-carriers (13.8 vs. 8.9%;
p=0.02). Carriers and non-carriers were similar
with respect to bilaterality, nodal status and
oestrogen receptor status.
4 4. .   G Ge en ne er ra al l   c co on nc cl lu us si io on ns s
Groups of individuals with an increased risk of
prostate cancer in the Polish population can be
identified by testing of specific variants in the NBS1,
BRCA1 and CHEK2 genes. It seems that analysis of the
RNASEL and MSR1 genes is not justified for this
purpose. The list of known genetic markers of high risk
of prostate cancer (in addition to strong family history
of prostate cancer and germline mutations in the BRCA2
gene) may be extended by specific mutations in the
NBS1, BRCA1 and CHEK2 genes in men with a positive
family history of prostate cancer in at least one 1
st or 2
nd
degree relative (the risk increased about 5-15 fold).
CHEK2 is multi-organ cancer susceptibility gene. 
It seems justified to consider surveillance of the prostate,
breast, thyroid, kidney and colon as an option for
carriers of CHEK2 mutations. It appears reasonable to
consider magnetic resonance imaging of the breast
beginning from the age of ~35 as an option for
mutation carriers, as CHEK2 mutations may predispose
to lobular and multifocal cancers in young women.
However, the establishment of surveillance protocols
for carriers of a CHEK2 mutation requires further
studies.
Most carriers of NBS1 and CHEK2 mutations report
negative family history of prostate, breast and
colorectal cancers. The use of DNA tests is the only
Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of originway to find carriers of these changes conferring
increased risk of tumour development. Identification of
low penetrance DNA variants may be very important
if the simultaneous presence of such alternations
and/or combinations with external risk factors in 
a carrier would add up to a clinically significant high
risk of tumour development.
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